Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8444777 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10NLRP3HMGCR | |
| SCHEMBL2997498 | 0.98 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10NLRP3HMGCR | |
| SCHEMBL8674650 | 0.98 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10NLRP3HMGCR | |
| SCHEMBL8674653 | 0.98 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10NLRP3HMGCR | |
| SCHEMBL8675010 | 0.95 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10NLRP3CHRM1 | |
| SCHEMBL24912279 | 0.90 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10NLRP3CHRM1 | |
| SCHEMBL17550206 | 0.90 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10NLRP3CHRM1 | |
| SCHEMBL15615426 | 0.87 | ALDH1A1 (0.34) | ALDH1A1LMNAHSD17B10NLRP3CHRM1 | |
| SCHEMBL16470991 | 0.87 | EPHX1 (0.36) | ALDH1A1LMNAHSD17B10NLRP3CYP3A4 | |
| SCHEMBL9680319 | 0.87 | CHRM1 (0.32) | ALDH1A1LMNAHSD17B10NLRP3HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-5859054-A | Leukotriene B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0741687-B1 | LEUKOTRIENE B4 DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| US-5783602-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-07-21 | — | — | US | disclosed |
| EP-0741686-B1 | NEW LEUKOTRIENE B4 DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AG (DE) | 1998-04-22 | — | — | EP | disclosed |
| EP-0741686-A1 | NEW LEUKOTRIENE B 4? DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020563-A1 | NEW LEUKOTRIENE B4 DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | CD4, P2RY1, P2RX7 | ALDH1A1 2720/4885LMNA 2969/4885HSD17B10 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.